If pain relief is not sufficient, or the patient

is resorting to illicit opioid use to control it, transfer to methadone maintenance may be needed. Discontinuation of buprenorphine maintenance While there is no legal limit to the length of buprenorphine maintenance, many patients ask to be withdrawn a few months after being maintained. The usual reasons are desire to be off all narcotics or the cost. Patients often have an unrealistic expectation of how easy it will be to remain abstinent144,145 and many (perhaps most) will relapse within a short period. Patients should be encouraged to remain on maintenance and, when possible, alternative solutions sought for issues like cost, eg, reducing frequency of visits, or exploring insurance options. Inhibitors,research,lifescience,medical There is no adequate data on the optimal length of time; each patient must be judged individually using issues such as previous relapses, addiction history, and lifestyle stability. It is not uncommon to need a number Inhibitors,research,lifescience,medical of episodes of opioid maintenance or even long-term maintenance. There is no consensus on the best way to withdraw from buprenorphine maintenance other than to do it gradually, eg, 2 mg/week until 4 mg is reached and then 1 mg decreased every Inhibitors,research,lifescience,medical other week or monthly. Clonidine may be useful in the final weeks to deal with the withdrawal symptoms. Relapse back to illicit opioid use should be taken seriously and the dose raised until the use stops. Continued use should probably be

handled by resuming full-scale maintenance. As yet, there are no adequate controlled studies comparing the ease or severity of withdrawal from maintained buprenorphine vs methadone patients, although Inhibitors,research,lifescience,medical earlier studies suggested that buprenorphine withdrawal might be better tolerated.146,147 Once the patient has completed detoxification, use of naltrexone for at least 3 months may help prevent relapse. The 1 -month depot naltrexone is preferable, but may be too expensive unless covered by insurance. Naltrexone Naltrexone was approved by

the FDA as an opioid antagonist in 1984. It is effective orally and Inhibitors,research,lifescience,medical is long-acting, depending upon dose. While methadone blocks heroin effects by cross-tolerance, naltrexone blocks the effects by competitive antagonism at the u receptor. The degree of blockade is a function of the concentrations of agonist to antagonist, L-NAME HCl and their receptor affinity. Because of the blocking action of naltrexone, self-administration of opioids at usual doses produces no euphoria so that either individuals cease heroin use or cease taking the naltrexone.148 Its long duration of action means that naltrexone can be given two or three times per week, but daily administration is usually preferred, both because of developing a regular habit of use and of creating a higher blockade. Less frequent administration is usually employed when an individual is taking monitored doses. {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| Tolerance does not develop to the opioid antagonism, even after almost 2 years of regular use.